ADC Therapeutics (ADCT) Q1 2026: Lotis-5 Sparks The Next Wave While Burn Remains the Backbone

ADC Therapeutics SA, trades as ADCT on the NYSE, posted its first-quarter 2026 results alongside a slate of operational updates. The headline is a dance between a growing product revenue line and an ongoing, high-burn R&D engine. In the near term, the company is pinning its hopes on Lotis-5 topline data in Q2 2026, with full Lotis-5 and Lotis-7 results due by year-end. The balance sheet remains relatively sturdy for a biotech in commercial-scale mode, with cash and cash equivalents around $231 million as of March 31, 2026, and a cash runway at least into 2028. For investors scanning earnings metrics, the release provides revenue numbers but no reported EPS or explicit EPS consensus, leaving the market to infer near-term earnings per share from burn and revenue trajectory.

Quarterly numbers and revenue mix

• First Quarter 2026 net product revenues: $20.0 million (vs. $17.4 million in Q1 2025).
• License revenues and royalties: $0.8 million (vs. $5.6 million in Q1 2025).
• Cost of product sales: $3.6 million.
• R&D expense: $19.9 million (vs. $28.9 million in Q1 2025).

The revenue growth is real on the product side, driven by volume and pricing above prior-year levels, though license revenue declined versus the prior period. The R&D burn is still meaningful, but it ticked down year over year, aided by a reallocation of some personnel costs and a deliberate shift away from external milestones tied to discontinued programs. The mix underscores the classic biotech pivot: monetize what you can now while you chase larger, riskier clinical milestones.

Note: the press release excerpt does not include an EPS figure or explicit EPS consensus, so readers should treat the EPS angle as implicit—any near-term earnings surprise or miss would hinge on GAAP results that are not disclosed in the excerpt.

Catalysts: what to watch and why it matters

The company reiterates a busy near-term horizon for its ZYNLONTA program (loncastuximab tesirine-lpyl) and the Lotis-5 and Lotis-7 trials in B-cell malignancies. Key timeline elements:

• LOTIS-5: topline results anticipated in 2Q 2026, with full results by year-end. A positive outcome could pave the way for a supplemental Biologics License Application (sBLA) to the FDA and possible compendia inclusion in 2027, followed by 2L+ DLBCL approval in the later window.
• LOTIS-7: ongoing Phase 1b study evaluating ZYNLONTA in combination with the bispecific antibody glofitamab, with enrollment expected to complete in the first half of 2026 and data targeted for release by year-end 2026. The company plans to share full data at a medical meeting and through publications.
• Investigator-Initiated Trials (IITs): ongoing IITs evaluating ZYNLONTA in additional B-cell malignancies, with data publication anticipated between late 2026 and mid-2027. Positive IIT data could influence regulatory and compendia considerations.

From a strategic perspective, ADCT is signaling that the near-term value lever is incremental data readouts on ZYNLONTA, supplemented by a potential regulatory pathway if LOTIS-5 data are favorable. The emphasis on 2026-2027 milestones suggests the stock and its peers will trade on clinical progress more than on current quarterly profitability for some time.

Financial health and burn: what keeps the lights on

Beyond the topline numbers, the release highlights ongoing operating discipline and liquidity planning. Notable financials include:

• Cash and cash equivalents: $231.0 million as of March 31, 2026.
• The company emphasizes an expected cash runway at least into 2028, a critical buffer as it navigates late-stage clinical development and potential regulatory submissions.

The revenue mix suggests that the business is gradually benefiting from product sell-through, but the P&L remains heavily front-loaded with R&D and operating costs. The R&D expense, while down from the prior year, still dominates spend at $19.9 million for the quarter, illustrating the classic biotech tension: fund the pipeline today or celebrate the revenue tailwind of a potential approved indication tomorrow.

Implications for ADC peers and the sector

ADCT’s path illustrates the broader ADC landscape: private-market appetite and public-market skepticism often hinge on the same variables—readouts from pivotal trials, regulatory pathways, and the ability to convert clinical milestones into a durable revenue stream. The LOTIS-5 potential sBLA and 2027 compendia opportunities will be watched by peers pursuing similar combinations or monotherapies in B-cell malignancies. If ADCT demonstrates robust, durable responses and manageable safety in LOTIS-5, it could lift sentiment for other ADCs in the category, potentially elevating revenue forecasts and the EPS consensus discussions around this cohort of companies. Conversely, a delayed or underwhelming LOTIS-5 readout could revalue clinical risk across ADCs targeting lymphoma indications, given the shared challenges of manufacturing costs, healthcare system pricing, and competitive dynamics.

Risks and forward-looking considerations

As with any story built on trial outcomes, the main risks are outcome-driven: LOTIS-5 and LOTIS-7 data must support a favorable regulatory path and, ideally, a longer-term revenue trajectory beyond a single product. The lack of a disclosed EPS figure means the near-term earnings surprise narrative hinges on how quickly R&D burn translates into clinical success and potential commercial milestones. Investors should also monitor the cadence of IIT data, regulatory communications, and potential horizon changes to the 2028 cash runway. In the sector, peers with parallel programs will be watching the same readouts and revising their own revenue forecasts and capital needs accordingly.

Conclusion: a hinge moment for ADCT and the ADC field

The Q1 2026 update positions ADCT at a crossroads: a palpable revenue uptick on product sales, a sizable but controlled R&D burn, and a horizon brimming with pivotal data. If Lotis-5 delivers as hoped and the company can convert that momentum into a timely regulatory filing and subsequent approvals, ADCT could shift from a pipeline-centric narrative to one anchored in a revenue-generating ZYNLONTA franchise. For peers, the message is clear: progress on the data front remains the ultimate catalyst, with capital discipline and clear regulatory pathways as supporting actors.